Current Partnering Activities
- Out-Licensing of EvitarTM (TTX 333) - Prevention of Adhesion Formation following abdominal/pelvic surgery:
- Markets available: US, EU, & ROW, including Japan, China, S. Korea, ASEAN, Australia, India, MENA, CIS, Russia and LATAM for EvitarTM. The first drug shown in clinical trials to prevent adhesion formation following laparoscopic surgery. For more information please contact us.
- Option to license at IND or Phase 1 (build to buy) of TTX 334-Endometriosis
- Worldwide markets available
- Temple will conduct preclinical and clinical work in conjunction with partner
- Option to license at IND or Phase 1 (build to buy) of TTX 334-Oncology platform:
- Worldwide markets available
- Researcher and Temple team have identified chemo resistant ovarian cancer as the preferred lead indication
- Data available in other cancers which can also be developed in conjunction with partner
Companies with a focus in the following areas would be interested in Temple's hospital and acute care portfolio:
- Hospital and acute care
- Oncology
- Fibrosis
- Women’s health
- Biosurgery
Our medical advisors, collaborators and researchers work at the following organizations.
